| Zelnorm (tegaserod) / Novartis |
NCT00171418: Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). |
|
|
| Completed | 3 | 54 | US | Tegaserod | Novartis | Gastroesophageal Reflux Disease (GERD) | | 02/05 | | |
NCT00141089: Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation. |
|
|
| Completed | 3 | 1026 | US | Tegaserod | Novartis | Chronic Constipation | | 02/05 | | |
NCT00171483: Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). |
|
|
| Completed | 3 | 30 | US | Tegaserod | Novartis | Gastroesophageal Reflux Disease (GERD) | | 04/05 | | |
NCT00139568: An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation |
|
|
| Completed | 3 | 600 | Europe | Tegaserod | Novartis | Constipation | | 10/05 | | |
NCT00232024: Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia |
|
|
| Completed | 3 | 1296 | US | Tegaserod | Novartis | Dyspepsia | | 05/06 | | |
NCT00171431: The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS) |
|
|
| Terminated | 3 | 20 | US | Tegaserod | Novartis Pharmaceuticals | Constipation Predominant, Irritable Bowel Syndrome (IBS-C) | 05/06 | 05/06 | | |
NCT00232089: Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia |
|
|
| Completed | 3 | 1296 | US | Tegaserod | Novartis | Dyspepsia | 06/06 | 06/06 | | |
| Completed | 3 | 359 | US | Tegaserod | Novartis | Dyspepsia | | 08/06 | | |
NCT00232102: Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia |
|
|
| Completed | 3 | 423 | US | Tegaserod | Novartis | Dyspepsia | | 08/06 | | |
NCT00171470: The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn. |
|
|
| Completed | 3 | 60 | US | Tegaserod | Novartis | Dyspepsia | | 08/06 | | |
NCT00171457: The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. |
|
|
| Completed | 3 | 24 | US | Tegaserod | Novartis | Heartburn, Dyspepsia | | 09/06 | | |
NCT00399659: Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. |
|
|
| Terminated | 3 | 360 | US | Tegaserod | Novartis | Opioid-induced Constipation | 04/07 | 04/07 | | |
NCT00414024: Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. |
|
|
| Terminated | 3 | 11 | US, RoW | Tegaserod | Novartis | Opioid-induced Constipation | 05/07 | 05/07 | | |
NCT00365820: Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain |
|
|
| Terminated | 2/3 | 670 | US | Tegaserod | Novartis | Constipation | 04/07 | 04/07 | | |
